Podcasts about biotech

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company's proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.Key Points From This Episode:00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles00:04:40 How their structure-first approach differs from peers like AbSci and Recursion00:07:04 Using cryo-EM to build proprietary protein interaction datasets00:10:57 Traditional drug discovery is random, expensive, and inefficient — here's how Generate is changing that00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI00:20:47 Going beyond efficiency: Unlocking access to undruggable biology00:24:48 Turning cryo-EM into a high-throughput data engine for model training00:31:20 The long-term vision: Patient-specific protein therapeutics00:40:00 Why scalability gives Generate an edge over traditional biotech00:47:52 The future of biotech as a research & development (R&D) sharing economy00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement

Dr. Shalabh Gupta is the founder of Unicycive, a biotech company working to simplify treatment for dialysis patients. He's also a physician, former Genentech executive, and someone who thinks deeply about careers, leadership, and the role of AI in healthcare. In this episode, we cover the problem of pill burden, how to reverse engineer your ... Read more The post Dr. Shalabh Gupta | Unicycive Founder on Biotech, Careers, Pill Burden, AI in Healthcare | EP188 appeared first on KazSource.

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Nvidia front and center ahead of results after the bell: Carl Quintanilla, Sara Eisen, and David Faber discussed what to expect tonight with Wedbush's Dan Ives – and broke down the key reports of the morning when it comes to the consumer… In addition to extra color from the CEO of Abercrombie & Fitch, as shares surge on record Q1 sales from the name.  Plus: Could President Trump's policies dent the dollar's dominance? Former Goldman Asset Management Chairman Jim O'Neill arguing yes – hear his defense, this hour… Along with Jefferies' top picks within one sector they say could be a major winner in the AI revolution, and a deep-dive on Trump's promises to take Fannie Mae and Freddie Mac public.  Also in focus: A live read from the ground at Bitcoin 2025; Why Loop Capital says tariffs could be a good thing for Apple; and Family offices get bullish – the details.   Squawk on the Street Disclaimer

After nearly two decades at GSK, Pascal Lestrate took a leap into Biotech, joining Vicebio as Chief Preclinical Science Officer. In this episode of Careers in Discovery, Pascal shares how the shift from big pharma to early-stage Biotech gave him a chance to return to hands-on science - and start with a blank page. We explore the pioneering work Vicebio is doing on multi-pathogen respiratory vaccines using molecular clamp technology, including how their approach could reduce the number of injections needed while improving vaccine stability and access in low-resource settings. Pascal also reflects on his rich and varied career, from molecular biology and immunology to regulatory affairs, quality systems, and digital transformation. Along the way, he shares lessons on navigating major career transitions, leading without deep technical expertise, and how curiosity, values, and a willingness to take up space have shaped his path.

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. Our conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.   This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome back to Impact Theory with Tom Bilyeu. In this episode, Drew and I take you through a whirlwind week where politics, world affairs, and tech innovation collide. We dissect Biden's shocking cancer diagnosis and what it means for the country, dig into Bernie Sanders' eyebrow-raising admission about the Democratic Party, and go deep on just how broken the government really is—and how (or if) it can ever be fixed. We tackle the big questions: What does it take to create a thriving middle class? Should we trust the government to spend more and do more, or do we need to completely rethink the machine? Are we living through a crisis of vision, where our leaders offer no North Star to inspire the country? And with news breaking on both the NIH's gain-of-function research and China's clampdown on gene editing, are we prepared for the next wave of scientific disruption? SHOWNOTES 00:00 – Biden's Cancer Diagnosis: Personal Impact & Political Fallout 03:14 – Are Our Leaders Too Old? The Real Problem with Political Power 07:08 – Lincoln's Legacy and the Ugly Truth Behind Political Narratives 10:58 – Why America Needs a New Vision (and Why We Don't Have One) 12:59 – Bernie Sanders & the Democratic Party: A Threat to Democracy? 15:39 – Can We Fix the System, or Is It Rigged Beyond Repair? 21:19 – Why Government Spending Is Broken (and How It Could Be Fixed) 27:00 – Positive Visions, Populism, and the Future of American Politics 32:03 – NIH, Wuhan Lab, and the Danger of Silencing Truth Seekers 43:31 – China, Gene Editing, and a New Age of Scientific Heresy 53:02 – Agentic AI: The Next Phase, What It Means, and How to Win 57:56 – Which Jobs Are Disappearing, and Which Will Survive the AI Revolution? 1:02:17 – Business in the Age of Hyper Turnover: What You Need to Know 1:09:36 – Ukraine, Russia, and Trump's Latest Negotiation: A Real Path to Peace? 1:10:13 – The Epstein Files: Government Secrecy and Conspiracy Theories CHECK OUT OUR SPONSORS Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Monarch Money: Use code THEORY at ⁠https://monarchmoney.com⁠ for 50% off your first year! Shopify: Sign up for your one-dollar-per-month trial period at ⁠https://shopify.com/impact⁠ Netsuite: Download the CFO's Guide to AI and Machine Learning at ⁠https://NetSuite.com/THEORY⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at ⁠https://mintmobile.com/impact.⁠  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business:⁠ join me here at ZERO TO FOUNDER⁠ SCALING a business:⁠ see if you qualify here.⁠ Get my battle-tested strategies and insights delivered weekly to your inbox:⁠ sign up here.⁠ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast,⁠ Tom Bilyeu's Mindset Playbook⁠ —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** LISTEN TO IMPACT THEORY AD FREE + BONUS EPISODES on APPLE PODCASTS:⁠ apple.co/impacttheory⁠ ********************************************************************** FOLLOW TOM: Instagram:⁠ https://www.instagram.com/tombilyeu/⁠ Tik Tok:⁠ https://www.tiktok.com/@tombilyeu?lang=en⁠ Twitter:⁠ https://twitter.com/tombilyeu⁠ YouTube:⁠ https://www.youtube.com/@TomBilyeu⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Tune in as Glenn Hunzinger, PwC's Health Industries Leader and Roel van den Akker, PwC's Pharma and Life Sciences Deals Leader discuss the rapid rise of China's biotech industry and what it means for U.S. pharmaceutical companies. They discuss the evolving role of Chinese biotech in the global innovation landscape and share perspectives on how U.S. pharmaceutical companies can thoughtfully assess opportunities, manage cross-border complexities, and build effective partnering and diligence strategies.  Discussion highlights:China's biotech industry is growing fast and becoming a global player, with U.S. companies increasingly looking to partner with Chinese firms on cutting-edge scienceU.S. pharma leaders are encouraged to move beyond skepticism and stay curious by building relationships, learning from local innovation, and exploring new partnership opportunitiesSuccessfully partnering with Chinese biotech firms requires a careful and well-structured approach that accounts for global complexity, protects data and IP, and uses creative deal structures like new company formations to manage risk and stay flexibleU.S. companies need to be proactive in order to stay competitive by actively exploring global innovation, understanding the risks, and having a clear strategy to bring high-potential science to U.S. patientsSpeakers:Roel Van den Akker, Pharmaceutical and Life Sciences Deals Leader Glenn Hunzinger, Partner, Health Industries Leader, PwCLinked materials:China's rise as a biotech innovation hub: 4 key strategic questions for US biopharma executivesFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

"If you really want to understand biology, you need to be able to represent it in the computer. If you can't model it, you can't really predict its behavior” In this episode of The Biotech Startups Podcast, Michael Antonov, Co-Founder of Oculus and Founder & CEO of Deep Origin, returns for the fourth installment of his series to share how his vision for holistic biological simulation evolved from Formic Labs into Deep Origin. Michael discusses the challenges of building a unified R&D platform for biotech, the current suite of Deep Origin's products, and how the company is making advanced drug discovery tools accessible to organizations of every size. He also dives into the company's philosophy, the lessons learned from previous ventures, and what's next as Deep Origin continues to scale its impact on the life sciences sector.

What does it really take to bring cutting-edge science out of the lab and into the world? In this episode of Inside Biotech, we sit down with Elizabeth Chabe, founder and CEO of High Touch Group, a strategic marketing firm specializing in biotech, medtech, and deep tech.Elizabeth shares her unique journey—from working in a structural engineering lab and helping scale pilot manufacturing projects, to becoming a trusted advisor to venture-backed startups across the life sciences. Along the way, she's led national campaigns at institutions like The Jackson Laboratory, helped scientists secure critical funding, and built a business that helps translate complex science into commercial success.Whether you're a researcher, founder, or science communicator, Elizabeth offers actionable advice on how to make sure your innovation doesn't stay hidden in the lab. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests! To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

From New Delhi to Kentucky to Biotech founder, Lalit Sharma's journey into drug discovery has been one of relentless learning and ambition. In this episode, Lalit shares how his love for chemistry led him from a PhD in organic synthesis to leading cutting-edge drug discovery programs that reached clinical trials. Now the founder and CEO of a stealth-mode company tackling the data gap in AI-driven drug design, he reflects on the lessons of building small, high-impact teams, the importance of lifelong learning, and why good storytelling is as essential as good science. We also dive into the realities of building a Biotech from scratch, the role of luck (and preparation), and the power of collaboration across disciplines.  

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The turbulence that has come with the Trump administration's policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury's editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China.The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury's editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk's transformation into a dominant player in obesity, is stepping down.Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago's thriving innovation ecosystem. If you're interested in attending, please register here. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655964#biotech #biopharma #pharma #lifescience #politics #policy #law00:01 - Sponsor Message: Jeito Capital05:05 - European Biotech's Moment?19:00 - Boston Pharma, Biomarin Deals29:41 - Novo Nordisk CEOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

The I Love CVille Show headlines: Could CVille Become The Silicon Valley Of Biotech? AlbCo Schools Right To Keep ‘Whole Truth History?' Is Ruckersville Volunteer Fire Dept. Being Shut Down? Carytown's Garden Grove Brewery Is Closing Nearly 350 Breweries Are Open Across Virginia If More Breweries Close, What Will Spaces Turn Into? People's Coalition Protest Expansion Of AlbCo Jail Downtown Executive Offices For Rent (Contact Us) Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

Join Charles River experts Sandy Kimber, Charlotte Cumper, and Claire Richards from our Portishead site for a discussion on what makes some viruses more contagious than others, how viruses can trick your immune system, and how vaccines can affect viral spread.

Legal and Strategic Insights on Chinese Investment in the U.S. with Chris PereiraWelcome to another insightful episode of the Asia Business Podcast, this week we have Chris Pereira, CEO of iMpact, a strategic advisory firm dedicated to assisting Chinese companies in global expansion. In this episode, Art and Chris engage in a candid discussion about the intricate challenges and opportunities Chinese companies face when entering the US market.The Current Landscape of US-China RelationsWith ongoing tensions between the US and China, businesses are navigating a complicated environment filled with tariffs, political tweets, and fluctuating regulations. The conversation opens with Chris highlighting that while tariffs remain a prominent topic, Chinese companies are more concerned with the stability of US regulations and policies, especially under an unpredictable political climate.Legal Concerns for Chinese BusinessesChris shares how his clients often question the potential risks associated with significant investments in the US. Art weighs in on the legal perspective, clarifying that while tweets may generate headlines, they have no legal standing. He reassures that even amidst political rhetoric, the US legal system maintains checks and balances that protect businesses from arbitrary decisions.Importance of Localizing Business EffortsThe discussion turns to the critical need for Chinese companies to localize efforts when establishing a presence in the US. Art and Chris emphasize the grassroots approach required to build local community relationships, often overlooked by companies accustomed to China's top-down decision-making processes. Understanding local governance and community impact is essential for success.The Political and Economic Impacts of TariffsTariffs, while significant, have not deterred Chinese companies from pursuing opportunities in the US market. Chris explains that many businesses manage to adapt their strategies, focusing on enhancing brand positioning as opposed to competing solely on price. Art adds that while tariffs can create uncertainties, they also encourage innovation and resilience among Chinese firms.The COVID-19 Aftermath and Geopolitical ConcernsChris expresses surprise at the continued discussions around COVID-19 within Chinese media, particularly in the context of legal actions against China. Art offers a legal interpretation, suggesting that lawsuits targeting governmental entities rather than private companies carry more symbolic meaning than enforceable outcomes.Future Outlook on US-China Business DynamicsDespite current challenges, both Art and Chris acknowledge an underlying optimism among Chinese businesses. The focus on strategic localization, investment in automation, and diversification into alternate markets like Southeast Asia and Europe signify adaptability and resilience. Art predicts a continued shift towards manufacturing localization in the US, driven by automation and stable regulatory environments.Final Insights and Moving ForwardAs the episode concludes, Art and Chris reflect on the shifting landscape of global business and the importance of adaptability and strategic foresight. The complexities of US-China relations underscore the need for businesses to remain informed and agile, leveraging diplomacy and legal expertise to navigate these uncertain waters.Timestamps00:00 Introduction and Guest Welcome00:36 Challenges and Opportunities for Chinese Companies in the US02:01 Legal Concerns and Tariffs06:34 Localizing Business Operations09:19 COVID-19 Lawsuits and Geopolitical Issues16:02 Tariff Situation and Future Outlook18:31 Brand Focus Over Price Competition19:06 Impact of Tariffs on Consumers and Suppliers20:44 China's Resilience and Market Shifts23:06 US Manufacturing and Investment Trends28:24 Automation and Complex Supply Chains31:17 Biotech and Pharma Industry Dynamics34:50 Concluding Thoughts and Future Outlook ProducerJacob ThomasFollow UsLinkedInApple Podcasts

We love to hear from our listeners. Send us a message. On this week's episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child's rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna's use of AI and machine learning for drug optimization, the company's planned use of basket trials, and more.   This episode is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Can a small biotech change cancer care—and turn a profit? Paul Romness, CEO of OS Therapies, shares how his five-person team took on one of the deadliest pediatric cancers, went public, and might just shake up the system. From biologics to Wall Street, this one's got it all. Sponsored by Dae Lee of Buchanan.

Kimon Hatza, Esq. of GrowthCounsel, LLC talks with Charlie Huntington of Life Sciences PA about Bio Tech news then they interview Ken Valuvanee, President and CEO of Facet Life Sciences discussing a better way to do scientific therapeutic development. The post Money Matters TV 25-17 Valuvanee appeared first on Money Matters TV.

Erum sits down with Michael Heltzen, CEO of eXoZymes, to dive into the transformative world of cell-free biomanufacturing. Michael shares the origin story of ExoZymes—from a student bioengineering dream at UCLA to ringing the NASDAQ bell—and unpacks why scalability, sustainability, and design thinking are central to the next generation of biotech. If you're curious about how biology can be engineered without living cells, what it takes to commercialize breakthrough science, or how new business models in synthetic biology are emerging, this is the episode for you. Get ready to rethink what's possible when biology breaks free from the cell wall.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 – Unlocking a New Era: Rethinking Natural Resources for the Future00:00:17 – SynBioBeta Afterglow: Late Nights, Big Ideas, and Bio Buzz00:02:39 – Breaking the Cell Wall: The Power of Cell-Free Biomanufacturing00:03:33 – Meet Michael Heltzen: The Visionary Behind the Next Bio Revolution00:09:54 – Inside NCTX: The Molecule That Might Change Everything00:16:06 – No Scale, No Impact: Tackling SynBio's Toughest Bottlenecks00:26:43 – From Supplements to Cures: Bio's Leap Across Sectors00:27:19 – AI x Enzymes: Cracking Nature's Code in Real Time00:28:06 – Making Biology Predictable: ML Meets Molecular Design00:30:14 – Faster Than Nature: How AI Shrinks Production Timelines00:33:29 – Go-to-Market Moves: Biotech Strategy for the Real World00:36:07 – Bio Click™: Targeted Enzymes with Industrial Precision00:38:38 – Life After the Bell: IPOs, Growth, and Big Bio Energy00:42:29 – Zooming Out: Big-Picture Thinking for What Comes NextLinks and Resources:eXoZymesNCTx BioClick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: biomanufacturing, cell free biomanufacturing, enzymes, nutraceuticals, biotech, pharmaceuticals, AI, spinoutsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Eric relays his dispatch from Dimension Capital's biotech summit in Park City, where the crowd was much more academic than the conferences we usually attend. Biotech stocks aren't doing great, meanwhile university funding cuts could spell trouble for drug research. Still, people were rosy about AI tools. We also took a temperature check on the state of fintech, which investors tell us is mixed. Everyone's hopeful about IPOs and streamlined stablecoins, but the dollar getting destabilized by the tariffs has some investors skittish. Later in the episode, Madeline explains how Trump's crackdown on immigration is spooking startup founders and employees. Timestamps: 00:42 Lineup of our upcoming fintech summit02:02 Eric's dispatch from Dimension Capital and Recursion's biotech summit09:22 Fintech IPOs and stablecoins en vogue18:50 Heightened immigration enforcement spooks startup employees

Ce vendredi 16 mai, les contre-performances de l'économie chinoise et la décision du groupe pharmaceutique français Sanofi d'affecter 20 milliards d'euros d'investissements aux États-Unis ont été abordés par Xavier Jaravel, professeur à la London School of Economics, Jean-Pierre Petit, président des Cahiers Verts de l'économie, et Christian Saint-Étienne, professeur au CNAM et membre du Cercle des Économistes, dans l'émission Les Experts, présentée par Nicolas Doze sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at times, with RFK Jr. firm on supporting the cuts but wavering on his stance on the MMR vaccine. AbbVie's ADC received accelerated approval for lung cancer treatment, FDA delays decision on Biohaven's application, and chaos ensues at the FDA's advisory committee planning office after workforce cuts. Sino Biological offers solutions for autoimmune disease research, with reagents for nearly 50 diseases. Novo Nordisk has invested $2.4 billion in a new oral obesity drug through a deal with Septerna, aiming to catch up with competitors in the oral weight loss space. AbbVie has committed $335 million upfront in a partnership with Adarx Pharmaceuticals for siRNA research, while GSK has abandoned a TIGIT therapy and instead acquired rights to a liver drug from Boston Pharmaceuticals for potential $2 billion deal. This news highlights the ongoing developments and investments in the pharmaceutical industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Breakthrough in Cancer TreatmentIn a groundbreaking study published in the Journal of Oncology, researchers have discovered a new combination of drugs that has shown promising results in treating pancreatic cancer. The study, which involved over 500 patients, found that the combination of drug A and drug B was able to significantly shrink tumors in over 70% of patients. This discovery has the potential to revolutionize the way we treat pancreatic cancer and could lead to improved outcomes for patients in the future.## FDA Approves New Drug for Alzheimer's DiseaseThe FDA has approved a new drug for the treatment of Alzheimer's disease, marking a major milestone in the fight against this devastating condition. The drug, which works by targeting the underlying causes of Alzheimer's, has shown promising results in clinical trials and is now available to patients across the country. This approval represents a significant step forward in our understanding of Alzheimer's disease and offers hope to the millions of people affected by this condition.## Vaccine Update: Delta VariantWith the rise of the Delta variant, there has been growing concern about the effectiveness of existing vaccines against this strain of the virus. However, recent studies have shown that current vaccines are still highly effective at preventing severe illness and hospitalization caused by the Delta variant. While breakthrough infections may occur, the vaccines are still providing robust protection against the worst outcomes of COVID-19. This is reassuring news as we continue to navigate the ongoing pandemic.## Collaboration Leads to New Drug DevelopmentA collaboration between two pharmaceutical companies has resulted in the development of a new drug for the treatment of rare genetic disorder. By pooling their resources and expertise, the two companies were able to accelerate the drug development process and bring this much-needed treatment to market sooner than would have been possible on their own. This successful collaboration serves as a model for future partnerships in the pharmaceutical industry and highlights the importance of working together to advance medical research.## ConclusionIn conclusion, these recent developments in cancer treatment, Alzheimer's disease, vaccine effectiveness, and collaborative drug development represent significant advances in the field of Pharma and Biotech. With ongoing research and innovation, we can look forward to more breakthroughs that will improve patient outcomes and change the landscape of healthcare. Thank you for listening to Pharma and Biotech daily, where we bring you the latest news and updates from the world of pharmaceuticals and biotechnology.

Welcome back to the second half of this eye-opening discussion with Ben Lamm, CEO of Colossal Biosciences. In Part 2, Tom and Ben dig even deeper, tackling the massive ethical questions and transformative possibilities that arise when humans hold the keys to edit and design life itself. Whether it's confronting the future of embryo screening, germline editing, the potential for designer babies, or the international arms race in biotechnology—no topic is off limits. Ben shares insider stories on Colossal's dire wolf project, explains misconceptions about cloning, and reveals the unexpected hurdles and breakthroughs in the world of synthetic biology. They discuss how these advances can directly impact human longevity, environmental crises like plastic pollution, and even set the stage for building the living cities and ocean habitats of tomorrow. This is a no-holds-barred, jam-packed episode for anyone intrigued by the future of engineering life—and the urgent questions we all must face as the bio-revolution unfolds. SHOWNOTES 33:30 – The Moral and Ethical Responsibility of ‘Playing God' 34:58 – Human Genome Editing, Embryo Selection, and the Coming Revolution in IVF 39:14 – The Personal Side: Ben's Own IVF Journey and Making Hard Choices 44:41 – The Slippery Slope: Intelligence, Disease, and Future Human Potential 51:36 – International Competition: US vs. China in Biotech and Human Enhancement 58:46 – Accelerating Gene Editing: Multiplexing, Cloning, and Animal Selection 1:09:12 – Rewilding and Ecosystem Impact: Fact vs. Jurassic Park Fiction 1:22:42 – The Longevity Escape Velocity and Radical Life Extension 1:44:08 – Innovations for the Planet: Enzymes That Break Down Plastic & Ocean Engineering 1:49:40 – The Future of Synthetic Biology: Designed Environments, Health, and Next-Gen Conservation FOLLOW BEN LAMM Twitter/X: @federallamm LinkedIn: Ben Lamm CHECK OUT OUR SPONSORS ButcherBox: Ready to level up your meals? Go to ⁠https://ButcherBox.com/impact⁠ to get $20 off your first box and FREE bacon for life with the Bilyeu Box! Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Shopify: Sign up for your one-dollar-per-month trial period at ⁠https://shopify.com/impact⁠ Netsuite: Download the CFO's Guide to AI and Machine Learning at ⁠https://NetSuite.com/THEORY⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at ⁠https://mintmobile.com/impact.⁠  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business:⁠ join me here at ZERO TO FOUNDER⁠ SCALING a business:⁠ see if you qualify here.⁠ Get my battle-tested strategies and insights delivered weekly to your inbox:⁠ sign up here.⁠ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast,⁠ Tom Bilyeu's Mindset Playbook⁠ —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** LISTEN TO IMPACT THEORY AD FREE + BONUS EPISODES on APPLE PODCASTS:⁠ apple.co/impacttheory⁠ ********************************************************************** FOLLOW TOM: Instagram:⁠ https://www.instagram.com/tombilyeu/⁠ Tik Tok:⁠ https://www.tiktok.com/@tombilyeu?lang=en⁠ Twitter:⁠ https://twitter.com/tombilyeu⁠ YouTube:⁠ https://www.youtube.com/@TomBilyeu⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Synopsis: What does bold biotech leadership look like in 2025? In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes. Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon's IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials. They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science. Biography: Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon's Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company's Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners. Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy. Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

How can public-private partnerships accelerate your biotech company's success? In this episode, host James Zanewicz, JD, LLM, RTTP, welcomes back Elizabeth Chabe, MBA—CEO of High Touch Group—for a deep dive into public-private partnerships (PPPs) and their untapped potential in the biotech sector. Together, they unpack how startups can strategically collaborate with public agencies and institutions, align on shared goals, and build milestone-driven programs that de-risk innovation while driving growth. In this episode, you'll learn: How public-private partnerships can help biotech startups overcome early-stage hurdles. What public funders are really looking for—and how to match their timelines and incentives. Practical tips for positioning your startup as a ready and reliable partner. Tune in to discover how aligning with the right public partner can unlock new opportunities for your biotech venture. Links: Connect with Elizabeth Chabe, MBA, and check out High Touch Group and her book, The Giant's Ladder. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Ashley Stahl and Elaine Hamm, PhD. Check out our first episode with Elizabeth: Find Funding for Your Biotech Startup - What Investors Look For. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

Send us a textAs the biotechnology sector races toward digital transformation, the buzz around Industry 4.0 - with its promise of interconnected systems, automation, and data-driven operations - has never been louder. But is the industry truly ready?In this episode, we speak with Tiago Matos, Associate Principal Scientist/Associate Director in Bioprocess Drug Substance and Commercialization at Merck & Co., who brings a grounded, insider view. Despite the hype, he says most of biopharma is still operating at an “Industry 3.2” level.With over a decade of experience in biologics and vaccines, Tiago leads teams pushing digital innovation forward - through tools like digital twins, advanced control strategies, and smart manufacturing platforms.Key takeaways from this episode:Biotech is slowly transitioning toward true Industry 4.0, through collaboration and strategic leadership.Digital twins aren't for everything. Focused use in platform processes yields the best return - broad implementation can be costly and complex.Regulators are ready. Far from being a barrier, they're encouraging innovation and open to new ideas.Curious to learn more? Check out the full blog post for deeper insights, and let us know your thoughts in the comments - how close do you think biomanufacturing is to a true digital revolution?Here is what other guests had to say on this topic:Episodes 5-6: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov;Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli;Episodes 121-122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger.Connect with Tiago Matos:LinkedIn: www.linkedin.com/in/tiagobmatosMerck & Co.: www.merck.comNext step:Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/callReady to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

In this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career within biotech/pharma organizations and some key lessons learned, such as taking advantage of your contacts and network, managing diverse workforces, and HR's role in creating an engaged team. Barney also discusses why she entered the HR field and the challenges of culture changes when transitioning from a small organization to a large company. AbbVie: https://www.abbvie.com/   

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research. This episode is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

"It's not about avoiding failure. It's about avoiding every scenario where you look back and say, ‘I could have done this differently and we wouldn't be here.'" In this episode, host Jon Chee talks with Bogdan Knezevic, co-founder and CEO of Kaleidoscope, about how smart R&D infrastructure decisions can make or break biotech startups. Bogdan shares his journey from scientist to founder and explains how Kaleidoscope empowers teams to harness their data, streamline collaboration, and extend their runway. The conversation spotlights real-world examples of how operational efficiency and the right tools create compounding advantages, why time is the true currency in biotech, and how accelerating drug development can have a profound impact for patients. Bogdan also reflects on the importance of learning by doing and paying it forward in the entrepreneurial journey.

Jeremy Bash explores the biotech battleground with former CIA science and technology chief Dawn Meyerriecks. Dawn, a key voice on the National Security Commission on Emerging Biotechnology, discusses the urgent need for US leadership to address critical vulnerabilities in the country's bio-industrial base. Dawn also makes a case for why powerful government-private sector alliances are essential to securing America's strategic edge in this vital domain.

What do sea turtles, science, and cannabis have in common? In this episode, Ellen Scanlon talks with Caitlyn Krebs, the CEO and co-founder of Nalu Bio, a San Francisco-based biotech company unlocking the therapeutic potential of cannabinoids. With Mother's Day around the corner, this conversation offers a timely look at what it takes to lead a high-growth startup, raise a family, and build the future of women's health, all at the same time. Caitlyn shares how her childhood in Hawaii sparked a love of science, what inspired her to co-found Nalu Bio, and why she's betting big on cannabinoids becoming as essential as vitamins. If you're curious about the science behind cannabis and want to feel inspired about the future of women's health, you'll be glad you got to know this innovative founder. "I believe cannabinoids are the next big thing, much like vitamins were 70 years ago. Back then, no one knew what vitamins did or what they were for, but now everyone takes them." - Caitlyn Krebs If you enjoyed this episode, we recommend Episode 286. How the Endocannabinoid System Could Transform Women's Health Hosted by Ellen Scanlon Sign up for Ellen's newsletter on Substack at https://dothepot.substack.com/ or at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠dothepot.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Spend the day with meld! While supplies last, Nalu Bio is offering free sample kits to How to Do the Pot listeners. Sign up for the meld newsletter at www.meldscience.com to claim your free kit and help shape the future of women's health. Includes 3 no-high blends: Move Free, Stay Calm, and Sleep Well.

https://garykaltbaum.com/

There are some incredible humans on planet Earth and Dr. Shoshana Shendelman is one of them. Dr. Shendelman is a PhD in cellular, molecular, and biophysical studies, and has committed her professional career to tackling some of medicine's toughest challenges, curing rare and underserved diseases. Dr. Shendelman sits on Columbia University's board of trustees and is vice chair of its medical board. She also IPO'd her company Applied Therapeutics, which eventually exceeded a billion-dollar market cap. But sometimes life takes unexpected turns. We can all relate. Applied Therapeutics and Dr. Shendelman's important research and development surrounding treatments for three diseases became entangled in an FDA procedural technical issue. Thank you, Dr. Shendelman, for joining me on Some Future Day to share your inspirational journey across the business of biotech, academia, and family. Wait until you hear about this incredible family! Enjoy.Order Marc's new book, "Some Future Day: How AI Is Going to Change Everything"Sign up for the Some Future Day Newsletter here: https://marcbeckman.substack.com/Episode Links:Dr. Shoshana on LinkedIn: https://www.linkedin.com/in/shoshana-shendelman-phd-8756926/Applied Therapeutics: https://www.appliedtherapeutics.com/To join the conversation, follow Marc Beckman here: YoutubeLinkedInTwitterInstagramTikTok

In this episode of Skin Anarchy, host Dr. Ekta sits down with Tony J. Abboud, Chief Commercial Officer of Core Biogenesis, for an eye-opening conversation on the cutting-edge science behind bioidentical proteins in skincare. Tony brings a biotech insider's perspective to the world of beauty, revealing how plant-based protein technology is unlocking a new era of truly effective, science-backed formulations.Core Biogenesis is tackling a long-standing challenge in skincare: the instability and inefficiency of traditional proteins and peptides. Tony breaks down how their team uses camelina sativa plants as natural bioreactors to produce high-purity, bioidentical growth factors like EGF and FGF—compounds that naturally support skin repair and collagen synthesis but decline with age. The innovation doesn't stop there: Core Biogenesis' breakthrough delivery system, oleosomes, stabilizes these proteins and enhances their penetration, leading to significantly better efficacy than traditional formats.This isn't just theoretical science—Tony explains how Core Biogenesis' oleosome-bound EGF retained 93% activity under stress conditions, compared to just 8% with standard EGF. With performance like this, consumers could see visible results in just 14 to 30 days. It's a game-changing advancement for skincare brands and users alike.Whether you're a skincare enthusiast, product formulator, or biotech curious, this episode offers a fascinating look into the future of skincare—one where biology, sustainability, and innovation converge. Tune in to discover how Core Biogenesis is rewriting the rules with plant-powered precision.CHAPTERS:(0:00) Introduction to Core Biogenesis(1:23) Tony's Background in Biotech and Skincare (2:04) The Importance of Ingredient Innovation (5:08) Core Biogenesis: Shifting Focus to Plant-Derived Proteins (10:23) The Science Behind Bioidentical Proteins (15:30) Stability Challenges in Skincare Formulations (17:01) The Impact of Bioidentical Proteins on Anti-Aging(22:03) Consumer Expectations and the Need for Faster Results (28:41) The Future of Bioidentical Proteins in Skincare To learn more about Core Biogenesis, visit https://www.corebiogenesis.co/skincareanarchy.Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

We love to hear from our listeners. Send us a message. On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, and building therapeutic franchise "skyscrapers." Tangular also shares his thoughts on commercializing RNAi therapies for larger patient populations, compared with rare disease populations, and reflects on changes in the biopharmaceutical sales and promotion model.This episode is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Tired of bedside burnout? Discover how Nurse Practitioner Ankita Shah transitioned from pediatric oncology to biotech and clinical research, using her NP skills in powerful new ways. Learn how NPs can land remote roles, navigate non-clinical careers, and unlock exciting job opportunities outside traditional clinicals.Follow Ankita on Instagram: https://www.instagram.com/npteeks/Follow Ankita on TikTok: https://www.tiktok.com/@npteeksCheck out Ankita's free job board for nurses, nurse practitioners, and PAs looking for biotech and pharma roles (including new to industry!) Https://theindustryclinician.myjboard.ioNPHire.com is the only job board designed exclusively for NPs. Over 100 jobs from some of healthcare's biggest employers are hiring - from telehealth to psych, acute care and more. Visit⁠ ⁠NPHire.com/success⁠⁠Visit ⁠www.nursesagainstinsanity.com⁠ to order the game, use promo code SUCCESSNP to save 20% on your order, and happy gaming!Visit Fred.ai to write your SOAP notes 10x faster and use code SUCCESSNP50 to get $50 off your first month when you subscribe!Check out our eBooks designed specifically for NP students navigating the clinical setting!⁠ ⁠https://bit.ly/SuccessNPebook⁠⁠Follow us on instagram: ⁠ ⁠@thesuccesnp⁠⁠Go to our website⁠ ⁠www.successnps.com⁠⁠

三腳貓很榮幸邀請到擁有5000+粉絲的臉書粉專「實驗鼠的七分鐘廢文」的實驗鼠來跟大家分享自己從博士班開始在粉專分享生活和實驗室裡的大小事（鬼故事）的契機，想更認識實驗鼠「阿鼠姊姊」嗎？想知道粉專名稱是怎麼來的嗎？想聽更多粉專裡面沒有講到的鬼故事嗎？那就絕對不要錯過這一集！ 工作人員 內容製作：實驗鼠的七分鐘廢文、若晴、Angel 剪輯：若晴 後製：若晴 文案：若晴 封面：雯薇 上架：若晴 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

In this episode of The Spoon Podcast, host Michael Wolf sits down with Carl-Emil Grøn, CEO and co-founder of Reshape Biotech, a Copenhagen-based company transforming the world of biotech research. While much of the tech industry has embraced automation and AI, Carl-Emil realized that biotech labs were still operating like it was the 1990s. Reshape is changing that by bringing robotics, machine learning, and a vast proprietary dataset to the lab bench—helping major companies like Unilever and Nestlé run millions of experiments and drastically accelerate the development of safe, natural ingredients. This conversation explores how AI is being used to reengineer food, personal care, and health products—and what it means for the future of the global food system. Learn more about your ad choices. Visit megaphone.fm/adchoices

Most accelerators fund ideas. Y Combinator funds founders—and transforms them. With a 1% acceptance rate and alumni behind 60% of the past decade's unicorns, YC knows what separates the founders who break through from those who burn out. It's not the flashiest résumé or the boldest pitch but something President Garry Tan says is far rarer: earnestness. In this conversation, Garry reveals why this is the key to success, and how it can make or break a startup. We also dive into how AI is reshaping the whole landscape of venture capital and what the future might look like when everyone has intelligence on tap.  If you care about innovation, agency, or the future of work, don't miss this episode.  Approximate timestamps: Subject to variation due to dynamically inserted ads. (00:02:39) The Success of Y Combinator (00:04:25) The Y Combinator Program (00:08:25) The Application Process (00:09:58) The Interview Process (00:16:16) The Challenge of Early Stage Investment (00:22:53) The Role of San Francisco in Innovation (00:28:32) The Ideal Founder (00:36:27) The Importance of Earnestness (00:42:17) The Changing Landscape of AI Companies (00:45:26) The Impact of Cloud Computing (00:50:11) Dysfunction with Silicon Valley (00:52:24) Forecast for the Tech Market (00:54:40) The Regulation of AI (00:55:56) The Need for Agency in Education (01:01:40) AI in Biotech and Manufacturing (01:07:24) The Issue of Data Access and The Legal Aspects of AI Outputs (01:13:34) The Role of Meta in AI Development (01:28:07) The Potential of AI in Decision Making (01:40:33) Defining AGI (01:42:03) The Use of AI and Prompting (01:47:09) AI Model Reasoning (01:49:48) The Competitive Advantage in AI (01:52:42) Investing in Big Tech Companies (01:55:47) The Role of Microsoft and Meta in AI (01:57:00) Learning from MrBeast: YouTube Channel Optimization (02:05:58) The Perception of Founders (02:08:23) The Reality of Startup Success Rates (02:09:34) The Impact of OpenAI (02:11:46) The Golden Age of Building Newsletter - The Brain Food newsletter delivers actionable insights and thoughtful ideas every Sunday. It takes 5 minutes to read, and it's completely free. Learn more and sign up at fs.blog/newsletter Upgrade — If you want to hear my thoughts and reflections at the end of the episode, join our membership: ⁠⁠⁠⁠⁠⁠⁠fs.blog/membership⁠⁠ and get your own private feed. Watch on YouTube: @tkppodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global health leadership. In this episode, Susan shares insights from her journey training in internal medicine during the early AIDS crisis, treating HIV-related cancers in Uganda, and developing groundbreaking cancer therapies like Herceptin and Avastin. She reflects on her leadership roles at UCSF and the Bill and Melinda Gates Foundation, offering lessons on guiding large-scale health initiatives, navigating uncertainty, and fostering scientific innovation. The conversation explores the promise of precision medicine, the integration of patient care and policy, and the evolving role of artificial intelligence in transforming diagnostics, drug development, and global access to care. We discuss: Susan's medical training, the start of the AIDS epidemic, and the transformative experiences that shaped her career [3:00]; Susan's experience working on the frontlines of the HIV/AIDS crisis in Uganda [12:30]; Susan's time working in general oncology and her transition to biotech where she helped develop taxol—a top-selling cancer drug [26:30]; Genentech's origins, and its groundbreaking use of recombinant DNA to develop biologic drugs [33:45]; Susan's move to Genentech, and her pivotal role in the development and success of Herceptin as a groundbreaking therapy in targeted oncology [44:00]; The rise of antibody-based cancer therapies: the development of Rituxan and Avastin [52:15]; The step-by-step drug development process and the scientific and strategic challenges involved [1:01:30]; The ethical and economic controversy surrounding Avastin's high cost and limited survival benefit [1:12:30]; Susan's tenure as chancellor at UCSF: leading during a financially strained period, and her strategic approach to fundraising and institutional development [1:14:45]; What Susan learned as CEO of the Bill and Melinda Gates Foundation: strategic processes and decision-making frameworks [1:26:00]; Susan's philosophy of leadership and how she sought to build an empowering, values-driven culture at the Gates Foundation [1:35:15]; The erosion of public trust in science during COVID, the communication failures around controversial treatments like ivermectin, and the need for better public health engagement and transparency [1:39:30]; The role of AI in transforming medicine: from drug development to cancer detection and beyond [1:53:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Today's guest is Carl Kawaja, a Portfolio Manager with Capital Group for over three decades. In today's episode, Carl shares insights into his investment philosophy, early experiences, and the current market landscape. He discusses the transformative impact of AI on semiconductor demand, the challenges posed by tariffs and supply chain dynamics, and the evolving landscape of sports gambling. Carl also reflects on the enduring value of certain companies, particularly in the context of evolving market conditions. (0:00) Starts (1:46) Intro (8:04) Compounding investments (13:47) Global investment insights (21:35) Market sentiment and trade policy discussions (28:01) Emerging markets (32:11) Tech, AI, and healthcare (37:34) Sports gaming industry (51:42) Biotech and healthcare investment opportunities (57:00) Carl's most memorable investment ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- Sponsor: YCharts enables financial advisors to make smarter investment decisions and better communicate with clients. Get 20% off your initial YCharts Professional subscription when you start your free trial. Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

The latest innovations in biotech are upending our approach to disease, longevity and climate change. Are we ready? This hour, TED speakers share ideas at the forefront of this new wave. Guests include co-founder of the Human Cell Atlas Aviv Regev, physical chemist Brad Ringeisen and immunoengineer Aaron Morris.TED Radio Hour+ subscribers now get access to bonus episodes, with more ideas from TED speakers and a behind the scenes look with our producers. A Plus subscription also lets you listen to regular episodes (like this one!) without sponsors. Sign-up at: plus.npr.org/ted.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy